Triferic study chosen as best abstract at conference, Rockwell Medical rallies

Rockwell Medical (RMTI +9.7%) is having a strong session.

Helping the cause may be the announcement that a Triferic study (PRIME) was selected as best abstract submitted to the 34th Annual Dialysis Conference.

In PRIME, Triferic (when regularly administered) lowered ESA usage "while maintaining iron balance and maximizing iron delivery."

RMTI hopes that between PRIME and the CRUISE trials, there is enough evidence to show that Triferic can "establish a new paradigm in iron therapy treatment for hemodialysis patients." (PR)

A bit of controversy surrounding this issue flared up last month thanks to a negative note out of Brean.

From other sites
Comments (2)
  • User 13300212
    , contributor
    Comment (1) | Send Message
    Brean should be investigated
    7 Jan 2014, 02:08 PM Reply Like
  • KamalDeepSingh
    , contributor
    Comment (1) | Send Message
    Nice information
    7 Jan 2014, 02:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs